A team led by scientists at The Scripps Research Institute (TSRI) has identified key signaling proteins in the inflammation process that contribute to the development of inflammatory diseases such as rheumatoid arthritis, psoriasis, sepsis and inflammatory bowel diseases. The finding highlights possible new ways of treating these inflammation disorders, which sicken or kill millions of people around the world each year.
"We hope our approach will lead to the development of drugs that augment current anti-inflammatory strategies," said TSRI Assistant Professor Young Jun Kang, who was the principal investigator for the new study, which was reported recently in the journal Science Signaling.
The inflammatory signaling pathway in question is an ancient one that can be found in a range of evolutionarily disparate species, from fruit flies to humans. Working as a primary defense system against bacteria and other intruders, it is triggered by a special set of receptors on white blood cells called Toll-like receptors (TLRs), which recognize molecular patterns associated with common microbes.
When they have detected a foe in this way, TLRs switch on the production, within their host cells, of a variety of inflammatory and anti-microbial compounds. These include the inflammatory protein TNF-? (tumor necrosis factor alpha), a cause of fever and malaise in systemic infections, and also a contributor—when produced for too long—to inflammatory disorders such as rheumatoid arthritis, psoriasis and inflammatory bowel disease.
TNF-? also features heavily in the condition called sepsis, a runaway process of inflammation in the bloodstream that can end up damaging vital organs, lowering blood pressure to life-threatening levels (septic shock) and causing blood to coagulate within vessels throughout the body. Sepsis as a result of bacterial infection kills a quarter of a million people in the U.S. each year.
As Kang and other investigators have shown, this type of inflammation typically has an early, acute phase and a late, sustained phase, the two phases being driven by distinct clusters of signaling molecules. Ideally, to treat or prevent inflammatory disorders, one would want to suppress the late phase while leaving the early phase intact to fight ordinary infections—and this has been Kang's aim for most of the past decade. In a study published in 2007 when he was a postdoctoral fellow at TSRI, Kang identified an immune cell protein called 4-1BBL as a critical factor in the late phase of a common type of inflammation triggered by the receptor TLR4.
In the new study, Kang and his colleagues examined 4-1BBL and its signaling partners in more detail to better understand the pathway and to find suitable drug targets.
In a series of experiments with cultured cells, Kang's colleagues Research Associates Jianhui Ma and Bo-Ram Bang were able to show that in late-phase, TLR4-triggered inflammation, 4-1BBL depends heavily on two other key proteins, TIRAP and IRAK2.
TIRAP appeared to be particularly important. Blocking its interaction with 4-1BBL by removing its gene from cells or by applying a specific chemical inhibitor, reduced late-phase inflammation—as shown by a big drop in TNF-? production. In mice with TLR4-triggered sepsis, inhibiting TIRAP again worked to reduce TNF-? levels and extended the animals' survival.
Kang and his laboratory now plan to test anti-inflammation therapeutic strategies, such as small chemicals and recombinant proteins that target the TIRAP-4-1BBL interaction, with the hope of eventually being able to develop a new class of anti-inflammatory therapy.
As Kang notes, current anti-inflammatory therapies typically aim to reduce TNF-? activity, for example with antibodies, after the protein has already been produced. His strategy has the potential advantage that it targets an earlier part of the process and thereby suppresses TNF-? production—nipping it in the bud, so to speak.
"We think that this will at least complement the current strategy," Kang said.
Explore further: Target for new Rx class for inflammatory disorders discovered
More information: "The Tumor Necrosis Family Member 4-1BBL Sustains Inflammation by Interacting with TLR Signaling Components During Late-Phase Activation," stke.sciencemag.org/cgi/content/abstract/6/295/ra87
Medical Xpress on facebook
Related Stories
Target for new Rx class for inflammatory disorders discovered
Oct 03, 2013
Research led by Charles Nichols, PhD, Associate Professor of Pharmacology at LSU Health Sciences Center New Orleans, describes a powerful new anti-inflammatory mechanism that could lead to the development of new oral medications ...
Inappropriate activation of an immune signaling pathway during infection leaves the body vulnerable to sepsis
Sep 26, 2012
The inflammatory response is a double-edged sword—it enables the body to mount a vigorous defense against infection, but can also inflict serious physiological damage if allowed to rampage uncontrolled. ...
Bio-hybrid device acts as 'thermostat' to control systemic inflammation in sepsis
May 14, 2012
A small, external bioreactor holding human cells pumped out an anti-inflammatory protein to prevent organ damage and other complications in a rat with acute inflammation caused by bacterial products in a model of sepsis, ...
Researchers probe the enigma of healing element that is also the enemy
Apr 03, 2013
The same factor in our immune system that is instrumental in enabling us to fight off severe and dangerous inflammatory ailments is also a player in doing the opposite at a later stage, causing the suppression of our immune ...
A boost in microRNA may protect against sepsis and other inflammatory diseases
May 24, 2012
Acute inflammatory diseases, such as sepsis, as well as chronic inflammatory diseases like diabetes and arthritis, develop as a result of sustained inflammation of the blood vessel wall. Researchers at Brigham and Women's ...
Recommended for you
Fresh advance in the diagnosis and control of childhood asthma
Oct 07, 2013
In a piece of research run at the Paediatric Service of the Hospital Universitario Donostia, Dr Paula Corcuera-Elosegui, assistant consultant in Infant Pneumology, has studied the validity of the exhaled ...
Specialized intestinal cells cause some cases of Crohn's disease
Oct 02, 2013
Scientists have discovered that Crohn's disease, the inflammatory bowel disorder, can originate from specialised intestinal cell type called Paneth cells. As such, they propose that small intestinal Crohn's disease might ...
Microbial restoration of the inflamed gut
Sep 30, 2013
A team led by gastroenterologists Sieglinde Angelberger and Walter Reinisch (Medical University Vienna) and microbiologists David Berry and Alexander Loy (University of Vienna) explored how a treatment called ...
Millions treated for asthma may be misdiagnosed
Sep 30, 2013
(Medical Xpress)—It's estimated that more than 26 million Americans have been diagnosed with asthma, but there is growing concern that many are being misdiagnosed or under-diagnosed and may be suffering from untreated conditions.
Collaborative effects of multiple bacterial strains in the gut may help prevent onset of certain inflammatory diseases
Sep 27, 2013
At first, it may sound alarming to learn that a population of bacteria in your gut is conspiring to suppress your immune system—however, this is actually good news. By identifying the strains responsible, ...
Chronic inflammation linked to less likelihood of healthy aging
Sep 16, 2013
Chronic exposure to high levels of interleukin-6 was associated with a significantly lower likelihood of healthy aging, according to a study in CMAJ (Canadian Medical Association Journal).
User comments
© Medical Xpress 2011-2013, Phys.org network
A team led by scientists at The Scripps Research Institute (TSRI) has identified key signaling proteins in the inflammation process that contribute to the development of inflammatory diseases such as rheumatoid arthritis, psoriasis, sepsis and inflammatory bowel diseases. The finding highlights possible new ways of treating these inflammation disorders, which sicken or kill millions of people around the world each year.
"We hope our approach will lead to the development of drugs that augment current anti-inflammatory strategies," said TSRI Assistant Professor Young Jun Kang, who was the principal investigator for the new study, which was reported recently in the journal Science Signaling.
The inflammatory signaling pathway in question is an ancient one that can be found in a range of evolutionarily disparate species, from fruit flies to humans. Working as a primary defense system against bacteria and other intruders, it is triggered by a special set of receptors on white blood cells called Toll-like receptors (TLRs), which recognize molecular patterns associated with common microbes.
When they have detected a foe in this way, TLRs switch on the production, within their host cells, of a variety of inflammatory and anti-microbial compounds. These include the inflammatory protein TNF-? (tumor necrosis factor alpha), a cause of fever and malaise in systemic infections, and also a contributor—when produced for too long—to inflammatory disorders such as rheumatoid arthritis, psoriasis and inflammatory bowel disease.
TNF-? also features heavily in the condition called sepsis, a runaway process of inflammation in the bloodstream that can end up damaging vital organs, lowering blood pressure to life-threatening levels (septic shock) and causing blood to coagulate within vessels throughout the body. Sepsis as a result of bacterial infection kills a quarter of a million people in the U.S. each year.
As Kang and other investigators have shown, this type of inflammation typically has an early, acute phase and a late, sustained phase, the two phases being driven by distinct clusters of signaling molecules. Ideally, to treat or prevent inflammatory disorders, one would want to suppress the late phase while leaving the early phase intact to fight ordinary infections—and this has been Kang's aim for most of the past decade. In a study published in 2007 when he was a postdoctoral fellow at TSRI, Kang identified an immune cell protein called 4-1BBL as a critical factor in the late phase of a common type of inflammation triggered by the receptor TLR4.
In the new study, Kang and his colleagues examined 4-1BBL and its signaling partners in more detail to better understand the pathway and to find suitable drug targets.
In a series of experiments with cultured cells, Kang's colleagues Research Associates Jianhui Ma and Bo-Ram Bang were able to show that in late-phase, TLR4-triggered inflammation, 4-1BBL depends heavily on two other key proteins, TIRAP and IRAK2.
TIRAP appeared to be particularly important. Blocking its interaction with 4-1BBL by removing its gene from cells or by applying a specific chemical inhibitor, reduced late-phase inflammation—as shown by a big drop in TNF-? production. In mice with TLR4-triggered sepsis, inhibiting TIRAP again worked to reduce TNF-? levels and extended the animals' survival.
Kang and his laboratory now plan to test anti-inflammation therapeutic strategies, such as small chemicals and recombinant proteins that target the TIRAP-4-1BBL interaction, with the hope of eventually being able to develop a new class of anti-inflammatory therapy.
As Kang notes, current anti-inflammatory therapies typically aim to reduce TNF-? activity, for example with antibodies, after the protein has already been produced. His strategy has the potential advantage that it targets an earlier part of the process and thereby suppresses TNF-? production—nipping it in the bud, so to speak.
"We think that this will at least complement the current strategy," Kang said.
Explore further: Target for new Rx class for inflammatory disorders discovered
More information: "The Tumor Necrosis Family Member 4-1BBL Sustains Inflammation by Interacting with TLR Signaling Components During Late-Phase Activation," stke.sciencemag.org/cgi/content/abstract/6/295/ra87
Medical Xpress on facebook
Related Stories
Target for new Rx class for inflammatory disorders discovered
Oct 03, 2013
Research led by Charles Nichols, PhD, Associate Professor of Pharmacology at LSU Health Sciences Center New Orleans, describes a powerful new anti-inflammatory mechanism that could lead to the development of new oral medications ...
Inappropriate activation of an immune signaling pathway during infection leaves the body vulnerable to sepsis
Sep 26, 2012
The inflammatory response is a double-edged sword—it enables the body to mount a vigorous defense against infection, but can also inflict serious physiological damage if allowed to rampage uncontrolled. ...
Bio-hybrid device acts as 'thermostat' to control systemic inflammation in sepsis
May 14, 2012
A small, external bioreactor holding human cells pumped out an anti-inflammatory protein to prevent organ damage and other complications in a rat with acute inflammation caused by bacterial products in a model of sepsis, ...
Researchers probe the enigma of healing element that is also the enemy
Apr 03, 2013
The same factor in our immune system that is instrumental in enabling us to fight off severe and dangerous inflammatory ailments is also a player in doing the opposite at a later stage, causing the suppression of our immune ...
A boost in microRNA may protect against sepsis and other inflammatory diseases
May 24, 2012
Acute inflammatory diseases, such as sepsis, as well as chronic inflammatory diseases like diabetes and arthritis, develop as a result of sustained inflammation of the blood vessel wall. Researchers at Brigham and Women's ...
Recommended for you
Fresh advance in the diagnosis and control of childhood asthma
Oct 07, 2013
In a piece of research run at the Paediatric Service of the Hospital Universitario Donostia, Dr Paula Corcuera-Elosegui, assistant consultant in Infant Pneumology, has studied the validity of the exhaled ...
Specialized intestinal cells cause some cases of Crohn's disease
Oct 02, 2013
Scientists have discovered that Crohn's disease, the inflammatory bowel disorder, can originate from specialised intestinal cell type called Paneth cells. As such, they propose that small intestinal Crohn's disease might ...
Microbial restoration of the inflamed gut
Sep 30, 2013
A team led by gastroenterologists Sieglinde Angelberger and Walter Reinisch (Medical University Vienna) and microbiologists David Berry and Alexander Loy (University of Vienna) explored how a treatment called ...
Millions treated for asthma may be misdiagnosed
Sep 30, 2013
(Medical Xpress)—It's estimated that more than 26 million Americans have been diagnosed with asthma, but there is growing concern that many are being misdiagnosed or under-diagnosed and may be suffering from untreated conditions.
Collaborative effects of multiple bacterial strains in the gut may help prevent onset of certain inflammatory diseases
Sep 27, 2013
At first, it may sound alarming to learn that a population of bacteria in your gut is conspiring to suppress your immune system—however, this is actually good news. By identifying the strains responsible, ...
Chronic inflammation linked to less likelihood of healthy aging
Sep 16, 2013
Chronic exposure to high levels of interleukin-6 was associated with a significantly lower likelihood of healthy aging, according to a study in CMAJ (Canadian Medical Association Journal).
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment